Check 35,000+ stocks against 26 valuation models and 37 quality factors

Shenzhen Hepalink Pharmaceutical (9989) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Shenzhen Hepalink Pharmaceutical HK$6.53, price HK$3.83, upside +70.7%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · Home China · ISIN CNE100003YN2

Thin data Sep 27, 2026

Shenzhen Hepalink Pharmaceutical

9989 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value HK$6.53 · Strongly undervalued (+70.7%)

✓Quality 64/100

!Weak Growth (revenue 5y +0.5 %/yr)

!Thin margins · 7.0% net margin (TTM)

✓Low debt · generates free cash flow

✓3.8% dividend yield · Sustainable

✓Ranks above peers (10/14)

!Narrow moat 35/100

!Evidence only low, so the estimate is less certain

!Weak on past: 12 out of 100

26 models, one by oneBear HK$6.53 to bull HK$7.65 Growth analysisrevenue history, year by year Quality 64/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Shenzhen Hepalink Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$2.22 – HK$10.04 · fair‑value band HK$6.53 – HK$7.65 · the HK$3.83 price screens below the HK$6.53 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Shenzhen Hepalink Pharmaceutical in your weekly email

Every Wednesday you see whether Shenzhen Hepalink Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Stock analysis

Shenzhen Hepalink Pharmaceutical (9989) currently trades at HK$3.83, while our model-based Fair Value estimate is HK$6.53, implying the stock looks roughly 41.4% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$13.93 per share, and 24 of the 26 models we run sit above the HK$3.83 price.

Bear case: the Earnings-Based group reads lowest at HK$2.63, and 2 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$6.53 (bear) to HK$7.65 (bull), the price of HK$3.83 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Shenzhen Hepalink Pharmaceutical reported revenue of 5.5B CNY in FY2025 versus 6.4B CNY in FY2021, a compound −3.7%/yr. Reported net income was 349M CNY in FY2025, compounding +9.8%/yr from FY2021.

Key figures

Market cap HK$6.1B (≈ $774M) · P/E ratio 13.8 · P/S ratio 0.88 · EPS (TTM) HK$0.2743 · Dividend yield 3.8% · Net margin 6.4% · Return on equity 3.0% · Return on assets (EBIT) 3.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 71%, 9989 screens cheaper than that median.

Fair Value models

Bear HK$6.53 Fair Value HK$6.53 Bull HK$7.65

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0978 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$14.05 HK$21.47 HK$32.15 80

Growth DCF HK$13.98 HK$20.76 HK$30.05 78

Owner Earnings HK$6.15 HK$9.13 HK$13.42 76

All 26 models by family

DCF Models

FCF DCF HK$14.05 HK$21.47 HK$32.15 80

Owner Earnings HK$6.15 HK$9.13 HK$13.42 76

5Y Revenue Exit HK$8.64 HK$12.07 HK$16.33 73

5Y EBITDA Exit HK$10.58 HK$15.89 HK$22.15 75

5Y P/E Exit HK$8.45 HK$11.70 HK$15.10 72

10Y Revenue Exit HK$10.53 HK$14.18 HK$19.01 67

10Y EBITDA Exit HK$11.81 HK$16.67 HK$23.28 69

10Y P/E Exit HK$10.54 HK$13.93 HK$18.11 65

Earnings-Based

Graham-Dodd HK$1.89 HK$7.46 HK$10.13 64

Lynch FV HK$1.84 HK$2.63 HK$3.42 61

PEG = 1.0 HK$1.84 HK$2.63 HK$3.42 57

EPV HK$4.48 HK$4.98 HK$5.39 74

Dividend Discount

Gordon GGM HK$2.67 HK$4.80 HK$6.61 68

DDM Multi-Stage HK$2.67 HK$4.39 HK$5.13 67

Multiples

P/E Multiple HK$4.59 HK$6.12 HK$7.65 63

P/S Multiple HK$3.55 HK$4.73 HK$5.91 58

P/B Multiple HK$3.55 HK$4.73 HK$5.91 55

EV/EBIT HK$7.29 HK$9.44 HK$11.60 66

EV/EBITDA HK$9.27 HK$12.08 HK$14.89 67

EV/Revenue HK$5.44 HK$7.42 HK$9.39 54

Asset-Based

NCAV (Graham) HK$4.79 HK$6.42 HK$9.58 54

Growth DCF

Growth DCF HK$13.98 HK$20.76 HK$30.05 78

Rev-Margin DCF HK$8.64 HK$12.22 HK$16.66 73

Economic Profit

Residual Income HK$6.58 HK$6.36 HK$6.34 76

ROIC Compounder HK$4.48 HK$4.98 HK$5.39 72

Growth Earnings

Growth-Adj P/E HK$3.37 HK$4.81 HK$6.25 67

Open the full fair value analysis →

Notify me when 9989 reaches fair value

Put 9989 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 64 · Market factors (momentum, volatility) 35

Profitability 24

Margins and returns on capital today

Quality Growth 32

Are margins and returns improving?

Cashflow 99

Earnings quality: real cash, not paper profit

Fin. Strength 57

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 85

Calm price path (market factor)

Momentum 22

Price trend over the last 3–12 months (market factor)

52W Momentum 2

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+3.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−8.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+0.5%

Start year 2020 (pandemic). Over 10 years: +9.1% a year

Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.0%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

−9.9%

Earnings growth per share plus dividend.

Earnings per share, growth per year−13.7%

Dividend (yield on the price)3.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−19.3% vs −2.8%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 12%

Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−27.4%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −28.6% a year for the price.

Watch 9989, get fair value alerts →

Compare Shenzhen Hepalink Pharmaceutical with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 64 · Above median

Fair Value upside +10.0% · Above median

Profitability

Return on equity (TTM) 3.0% · Below median

Return on assets 2.2% · Below median

Net margin (TTM) 7.0% · Below median

Operating margin (TTM) 14.4% · Above median

Growth and dividend

Revenue growth −4.5% · Below median

Dividend yield (TTM) 3.8% · Top 25%

Balance sheet

Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 13.8× · Cheapest 25%

P/B 0.43× · Cheapest 25%

P/S (TTM) 0.96× · Cheapest 25%

P/FCF 3.3× · Cheapest 25%

EV/EBITDA 4.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)47 · sector 14

FUTURE (revenue growth)0 · sector 26

PAST (return on equity)12 · sector 29

HEALTH (low debt)99 · sector 96

DIVIDEND (yield)76 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shenzhen Hepalink Pharmaceutical · Fair Value
HK$6.53 +41%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/9989" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shenzhen Hepalink Pharmaceutical  · Fair Value</span><br><b style="font-size:20px">HK$6.53</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+41%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shenzhen Hepalink Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/9989

Frequently asked questions

Is Shenzhen Hepalink Pharmaceutical (9989) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$6.53 versus a price of HK$3.83, about +71% upside (undervalued).

What is the fair value of 9989?

Our model-based fair value for Shenzhen Hepalink Pharmaceutical is HK$6.53 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$3.83.

What is the quality score of 9989?

Shenzhen Hepalink Pharmaceutical has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shenzhen Hepalink Pharmaceutical (9989)?

Our model-based price target is the fair value of HK$6.53 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$6.53, optimistic scenario HK$7.65. It is a calculation from audited fundamentals, not an analyst target.

What is the Shenzhen Hepalink Pharmaceutical stock forecast for 2026?

Our models put fair value at HK$6.53, about +71% upside versus a price of HK$3.83 (undervalued). Cautious scenario HK$6.53, optimistic scenario HK$7.65. The calculation is refreshed regularly with new filings.

What is the revenue of Shenzhen Hepalink Pharmaceutical (9989)?

Shenzhen Hepalink Pharmaceutical reported trailing-twelve-month revenue of about 5.4B CNY (latest available figure, as of Sep 27, 2026).

Does Shenzhen Hepalink Pharmaceutical pay a dividend?

Shenzhen Hepalink Pharmaceutical currently shows a dividend yield of about 3.79% relative to its recent price (as of Sep 27, 2026).

What growth is priced into Shenzhen Hepalink Pharmaceutical (9989)?

For today's price to be fair in a discounted-cash-flow model, Shenzhen Hepalink Pharmaceutical would have to grow free cash flow by -27.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.6 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 9989 use?

Our models discount Shenzhen Hepalink Pharmaceutical at 10.3 %: a base by market capitalisation (small), damped by beta 0.30, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shenzhen Hepalink Pharmaceutical that is -27.4 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has Shenzhen Hepalink Pharmaceutical (9989) delivered so far?

Over the past 5 years revenue at Shenzhen Hepalink Pharmaceutical grew +0.6 % a year. The price currently implies -27.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Shenzhen Hepalink Pharmaceutical (9989) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Shenzhen Hepalink Pharmaceutical (-27.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Shenzhen Hepalink Pharmaceutical (9989)?

The free-cash-flow yield on the price is 33.18 %: that much free cash flow Shenzhen Hepalink Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Shenzhen Hepalink Pharmaceutical (9989)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Hepalink Pharmaceutical it is HK$6.53 per share (as of Sep 27, 2026), against a price of HK$3.83. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Shenzhen Hepalink Pharmaceutical stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 9989 trades below its calculated fair value: price HK$3.83, fair value HK$6.53, a gap of about +71% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 9989?

No. The price is what the market pays today (HK$3.83); the fair value is what the company's own numbers justify (HK$6.53). For Shenzhen Hepalink Pharmaceutical the two are HK$2.71 per share apart. That gap is exactly why we show both numbers side by side.

How much is Shenzhen Hepalink Pharmaceutical worth?

The market values Shenzhen Hepalink Pharmaceutical at about HK$6.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$3.83; our models calculate a fair value of HK$6.53 per share.

What do the bullish and bearish scenarios say about 9989?

Our models span a range for Shenzhen Hepalink Pharmaceutical : cautious scenario HK$6.53, base HK$6.53, optimistic HK$7.65 per share (as of Sep 27, 2026, price HK$3.83). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 9989?

Shenzhen Hepalink Pharmaceutical trades at a price-to-earnings ratio of 13.8 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$6.53 is built from several models across several years. Other multiples: P/B 0.4, P/S 1.0, EV/EBITDA 4.4.

How solid is the balance sheet of Shenzhen Hepalink Pharmaceutical (9989)?

Balance-sheet figures for Shenzhen Hepalink Pharmaceutical (as of Sep 27, 2026): return on equity 3.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.

How far is 9989 from its 52-week high?

Shenzhen Hepalink Pharmaceutical trades at HK$3.83, about 31% below its 52-week high of HK$5.52 and 2% above the low of HK$3.76 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of HK$6.53 is for.

Which stocks are comparable to Shenzhen Hepalink Pharmaceutical ?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Shenzhen Hepalink Pharmaceutical stock attractive at the current price?

The data as of Sep 27, 2026: price HK$3.83, calculated fair value HK$6.53 (+71%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 9989 calculated?

We run Shenzhen Hepalink Pharmaceutical through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$6.53, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Shenzhen Hepalink Pharmaceutical currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Shenzhen Hepalink Pharmaceutical (9989)?

The closing price on Oct 2, 2026 was HK$3.83. Our model-based fair value is HK$6.53, about +71% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Shenzhen Hepalink Pharmaceutical right now?

The price is below even our cautious bear case (HK$6.53). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.

Where does the earnings growth of Shenzhen Hepalink Pharmaceutical (9989) come from?

Earnings per share at Shenzhen Hepalink Pharmaceutical grew −0.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.3 %, EBIT margin −5.8 %, tax rate +0.4 %, residual (interest, one-offs) −2.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Shenzhen Hepalink Pharmaceutical

How large is the market capitalisation of Shenzhen Hepalink Pharmaceutical (9989)?

The market capitalisation of Shenzhen Hepalink Pharmaceutical is HK$6.1B (≈ $774M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Shenzhen Hepalink Pharmaceutical (9989)?

The price-to-sales ratio of Shenzhen Hepalink Pharmaceutical is 0.88 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Shenzhen Hepalink Pharmaceutical (9989)?

Earnings per share at Shenzhen Hepalink Pharmaceutical are HK$0.2743 (price ÷ EPS = P/E 13.8). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Shenzhen Hepalink Pharmaceutical (9989)?

The dividend yield of Shenzhen Hepalink Pharmaceutical is 3.8% (payout 52.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Shenzhen Hepalink Pharmaceutical (9989)?

The net margin of Shenzhen Hepalink Pharmaceutical is 6.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Shenzhen Hepalink Pharmaceutical (9989)?

The return on equity (ROE) of Shenzhen Hepalink Pharmaceutical is 3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Shenzhen Hepalink Pharmaceutical (9989)?

On an EBIT basis the return on assets of Shenzhen Hepalink Pharmaceutical is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Shenzhen Hepalink Pharmaceutical (9989)?

The operating margin of Shenzhen Hepalink Pharmaceutical is 14.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Shenzhen Hepalink Pharmaceutical (9989)?

Revenue at Shenzhen Hepalink Pharmaceutical is growing −4.5% versus a year earlier (3y avg −8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Shenzhen Hepalink Pharmaceutical (9989)?

Earnings per share at Shenzhen Hepalink Pharmaceutical are growing +19.8% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Shenzhen Hepalink Pharmaceutical (9989) carry?

The net debt of Shenzhen Hepalink Pharmaceutical is 763M CNY (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Shenzhen Hepalink Pharmaceutical in the live analysis

One click puts Shenzhen Hepalink Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.